摘要

We evaluate the efficacy and safety of GreenLight HPS (TM) laser photoselective vaporization prostatectomy (PVP) for the treatment of benign prostatic hyperplasia (BPH) with different prostate configuration. Patients were stratified into two groups: bilobe (group I) and trilobe (group II) BPH. Transurethral PVP was performed using a 120 W GreenLight HPS (TM) side-firing laser system. American Urological Association Symptom Score (AUASS), Quality of Life (QoL) score, maximum flow rate (Q (max)), and postvoid residual (PVR) were measured preoperatively and at 1 and 4 weeks and 3, 6, 12, 18, 24 and 36 months postoperatively. A number of 160 consecutive patients were identified (I: 86, II: 74). Among the preoperative parameters, there were significant differences (p < 0.05) in prostate volume (I: 46.0 +/- 19.8; II: 87.5 +/- 39.6 ml), Q (max) (I: 9.9 +/- 3.9; II: 8.7 +/- 3.5 ml/sec), PVR (I: 59.2 +/- 124.6; II: 97.7 +/- 119.1 ml) and PSA (I: 1.4 +/- 1.4; II: 3.6 +/- 2.6 ng/ml), while AUASS and QoL were similar (p > 0.05). Significant differences (p < 0.05) in laser utilization (I: 9.5 +/- 6.6; II: 19.5 +/- 11.6 min) and energy usage (I: 63.1 +/- 43.9; II: 132.5 +/- 81.1 kJ) were noted. Clinical outcomes (AUASS, QoL, Q (max), and PVR) showed immediate and stable improvement from baseline (p < 0.05) within each group, but no significant differences between the two groups were observed during the follow-up period (p > 0.05). The incidences of adverse events were low and similar in both groups. Our experience suggests that BPH configuration has little effect on the efficacy and safety of GreenLight HPS (TM) laser PVP.